Looking at Su Muxin, who picked up the scroll and looked intoxicated, Lin Yu was about to speak, but the phone rang suddenly.

After a glance, Lin Yu found that it was Ouyang Lei who called, and without thinking too much, he connected directly.

In the next second, Ouyang Lei's familiar voice came from the other end of the phone: "Chairman, I have already arranged a professional team for tumor immunotherapy, and the topic of technology sharing has been released, so I sent you over to teach the core technology." ”

Hearing the news, Lin Yu, who had just arrived home and didn't even have a hot butt, suddenly raised his eyebrows, but he finally responded: "Well, okay, I'll be there later." ”

After hanging up the phone, Lin Yu couldn't help but glance at Su Muyun, and shrugged helplessly: "The company has something to do, I need to go there, and I guess I haven't come back for lunch." ”

"It's okay, you go, work matters." Su Muyun smiled softly, and immediately noticed that Lin Yu's coat was a little untidy, so he walked up to him and gently smoothed out every wrinkle on his clothes.

At this time, whether it is her expression, movements or look, she is like a gentle and considerate wife waiting for her husband to come home.

Seeing this scene, Lin Yu couldn't help but raise a warm smile on his face, and couldn't help lowering his head and kissing Su Muyun's forehead: "I'm leaving." ”

"Hmm..."

Su Muyun nodded, and immediately watched Lin Yu disappear from sight at the door.

Seeing this, Su Muxin, who was holding the picture scroll on the side, couldn't help but pout, and her originally excited mood suddenly turned speechless.

Good guy, as soon as you come back, you will sprinkle dog food, you really don't think of yourself as a human being.

Thinking of this, Su Muxin couldn't help but snort lightly, and immediately walked briskly towards her bedroom with the picture scroll and a large pile of shopping bags.

After leaving home, Lin Yu drove straight to the immuno-oncology R&D center.

Along the way, what made Lin Yu speechless was that Zhao Yu, the director of the Special Intelligence Bureau, suddenly called him, saying that they had completed the formation of the company, and the team of nanomachinery experts was also ready, just waiting for him.

Hearing this coincidental news, Lin Yu hesitated for a while, and finally asked them to wait for the time being, and then talk about it when he was busy with the company's affairs.

There is no way, because compared with the manufacture of nano holographic projectors, the cancer immunotherapy on the company's side is obviously more urgent.

Moreover, according to Lin Yu's estimate, Xiaoyi's next course of treatment should be about to start, but now the second shot of neuroma antibodies has not yet started.

Half an hour later, Lin Yu drove to the R&D center, and under Ouyang Lei's report, the two walked in together.

After a while, Lin Yu, who understood the situation, put on white overalls and a white mask in the fitting room, quickly entered the laboratory, and once again skillfully manufactured the second shot of neuroma antibody with the tumor immunity team who did neuroma antibody last time.

It's just that this time is different from last time, Lin Yu needs to teach core technologies to people selected from the team while doing neuroma antibodies.

It's just that what makes Lin Yu a little helpless is that although he spoke very clearly and in detail, because this core technology is too complicated, the other party has a hard time listening.

In fact, this is normal, because the immunotherapy for this neuroma is developed by Lin Yu according to the CAR-T cell technology rewarded by the system, combined with the self-development of the superbrain, which must be difficult.

In this regard, Lin Yu also thought of a way, that is, to split the core technology into three parts, and handed them over to three people to learn, so that they could manufacture them first, and then combine the finished neuroma antibodies.

After the three of them have learned, Lin Yu can let them split the core technologies they have learned, let them become teachers, teach the next level of personnel, and finally realize the production line operation.

It's just that although Lin Yu's idea is very beautiful, it is not so easy to practice.

Therefore, after making the second shot of neuroma antibody in the evening, Lin Yu was sad to find that the first three people to learn the core technology basically only understood about five percent.

In the face of Lin Yu's helplessness, the three people who learned the core technology also turned red, and they were embarrassed to apologize to Lin Yu.

In fact, they can't be blamed, who makes people full of gaps between people.

For this situation, Lin Yu could only comfort the three of them and let them continue to practice, while he drove home.

In the following days, Lin Yu can be said to be running back and forth between home and the company at two o'clock every day.

However, what made Lin Yu a little relieved was that the speed and efficiency of the three people who learned the core technology increased with the passage of time under their own teaching.

In the blink of an eye, half a month passed in a blink of an eye.

11 p.m. on August 14th.

In the GMP laboratory, researchers wearing white masks and white overalls are tightly enclosed in the center of a laboratory table.

To be precise, they were gathered around a special electronic device.

Soon, under the gaze of everyone, the rows of data on the display screen of the electronic instrument began to be continuously refreshed, and finally gradually frozen.

Neuroblastoma reduction and other remissions.

Partial response rate: 85%

Complete response rate: 89%

Overall response rate: 91%

Solid and non-solid tumor control rate: 93%

Adverse effects.

………

"Hahahaha, the overall remission rate reached 91%, and we succeeded!"

Looking at this data, the three researchers standing at the front of the instrument suddenly shouted excitedly, and immediately hugged each other with excitement.

After hearing the news, the entire research team also clapped their hands with smiles on their faces.

Compared with everyone's excitement, Lin Yu, who was sitting not far away waiting for the result, finally breathed a sigh of relief after hearing the news, and a smile appeared on his face.

It's been more than ten days, and these three people have finally succeeded in getting a neuroma antibody, which is really not easy.

After a moment of emotion, Lin Yu got up and walked over, and said with a smile: "The total remission rate has reached 91%, and it is only 4% short of the highest total remission rate, you have done a very good job." ”

"Where, this is all the credit of the chairman, without the careful teaching of the chairman, we would not have been able to make neuroma antibodies."

"That's right, in fact, the hardest work is still the chairman, you not only developed the immunotherapy for neuroma, but also spent time and effort to teach us personally, your credit is the greatest."

"That's right, we're just standing on your shoulders, chairman, and that's nothing."

In the face of Lin Yu's praise, the three people who learned the core technology looked at Lin Yu sincerely, and said from the bottom of their hearts.

"It's not that exaggerated."

Seeing this, Lin Yu just smiled and waved his hand: "Okay, the next thing will be left to you to solve, I have only one requirement, that is, to achieve large-scale supply as soon as possible, no problem, right?" ”

"No problem!"

Purple Pen Literature